Jeffrey L Gunter

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Methodological considerations for measuring rates of brain atrophy
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 18:16-24. 2003
  2. pmc Measurement of MRI scanner performance with the ADNI phantom
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA
    Med Phys 36:2193-205. 2009
  3. pmc Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Arch Neurol 69:856-67. 2012
  4. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
  5. pmc An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 71:765-75. 2012
  6. pmc Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
    Clifford R Jack
    From the Departments of Radiology C R J, V L, P V, D T J, M L S, J L G, B E G, Health Sciences Research H J W, S D W, M M M, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 81:1732-40. 2013
  7. pmc Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Neurol Neurosurg Psychiatry 84:1357-64. 2013
  8. pmc Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
    Clifford R Jack
    From the Departments of Radiology C R J, P V, M L S, J L G, V L, B E G, Health Sciences Research H J W, M M M, S D W, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 82:1605-12. 2014
  9. pmc Brain injury biomarkers are not dependent on β-amyloid in normal elderly
    David S Knopman
    Department of Neurology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN Mayo Clinic Alzheimer s Disease Research Center, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN
    Ann Neurol 73:472-80. 2013
  10. pmc Effect of lifestyle activities on Alzheimer disease biomarkers and cognition
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Ann Neurol 72:730-8. 2012

Detail Information

Publications46

  1. pmc Methodological considerations for measuring rates of brain atrophy
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 18:16-24. 2003
    ..To systematically compare two techniques for measuring brain atrophy rates from serial magnetic resonance imaging (MRI) studies...
  2. pmc Measurement of MRI scanner performance with the ADNI phantom
    Jeffrey L Gunter
    Mayo Clinic and Foundation, Rochester, Minnesota 55902, USA
    Med Phys 36:2193-205. 2009
    ..If undetected, these errors would have contributed to imprecision in quantitative metrics at over 25% of all enrolling ADNI sites...
  3. pmc Shapes of the trajectories of 5 major biomarkers of Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Arch Neurol 69:856-67. 2012
    ..To characterize the shape of the trajectories of Alzheimer disease biomarkers as a function of Mini-Mental State Examination (MMSE) score...
  4. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
    ....
  5. pmc An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 71:765-75. 2012
    ..A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines...
  6. pmc Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
    Clifford R Jack
    From the Departments of Radiology C R J, V L, P V, D T J, M L S, J L G, B E G, Health Sciences Research H J W, S D W, M M M, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 81:1732-40. 2013
    ..To estimate the incidence of and to characterize cognitive and imaging findings associated with incident amyloid PET positivity...
  7. pmc Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
    J Neurol Neurosurg Psychiatry 84:1357-64. 2013
    ....
  8. pmc Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
    Clifford R Jack
    From the Departments of Radiology C R J, P V, M L S, J L G, V L, B E G, Health Sciences Research H J W, M M M, S D W, V S P, and Neurology D S K, R C P, Mayo Clinic and Foundation, Rochester, MN
    Neurology 82:1605-12. 2014
    ....
  9. pmc Brain injury biomarkers are not dependent on β-amyloid in normal elderly
    David S Knopman
    Department of Neurology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN Mayo Clinic Alzheimer s Disease Research Center, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN
    Ann Neurol 73:472-80. 2013
    ..The characteristics of the sNAP group are poorly understood...
  10. pmc Effect of lifestyle activities on Alzheimer disease biomarkers and cognition
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Ann Neurol 72:730-8. 2012
    ....
  11. pmc Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
    ..8%). The proposed approach establishes a direct a priori relationship between specific topographic patterns on MRI and "gold standard" of pathology which can then be used to predict underlying dementia pathology in new incoming patients...
  12. pmc Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Brain 133:3336-48. 2010
    ....
  13. pmc Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia
    David S Knopman
    From the Departments of Neurology D S K, P V, M M Mielke, R O R, B F B, D T J, R C P and Radiology C R J, V J L, K K, J L G, M L S, D T J, Mayo Clinic Alzheimer s Disease Research Center D S K, C R J, B F B, D T J, R C P, Division of Biomedical Statistics and Informatics, Department of Health Sciences Research H J W, S D W, Division of Epidemiology, Department of Health Sciences Research M M Mielke, R O R, R C P, and Department of Psychiatry, Division of Psychology M M Machulda, Mayo Clinic and Foundation, Rochester, MN
    Neurology 87:691-8. 2016
    ..To examine neurodegenerative imaging biomarkers in Alzheimer disease (AD) dementia from middle to old age...
  14. pmc Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE
    Christopher G Schwarz
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, United States Electronic address
    Neuroimage . 2016
    ..In this work, we present a thorough comparison of methods to measure change in β-amyloid over time using Pittsburgh Compound B (PiB) PET imaging...
  15. pmc Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Neurobiol Aging 46:32-42. 2016
    ..Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway. ..
  16. pmc Sample size calculations for clinical trials targeting tauopathies: a new potential disease target
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA
    J Neurol 262:2064-72. 2015
    ..The small sample size estimates demonstrate feasibility for including progressive apraxia of speech in future clinical treatment trials targeting tau...
  17. pmc Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neuroimage Clin 11:90-8. 2016
    ....
  18. pmc Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota2Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota
    JAMA Neurol 72:1475-83. 2015
    ..To understand how a model of Alzheimer disease pathophysiology based on β-amyloidosis and neurodegeneration predicts the regional anatomic expansion of hypometabolism and atrophy in persons with mild cognitive impairment (MCI)...
  19. pmc Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, Minnesota
    JAMA Neurol 72:511-9. 2015
    ..Ideally, the full adult age spectrum should be included to assess brain imaging findings associated with typical aging...
  20. pmc Brain β-amyloid load approaches a plateau
    Clifford R Jack
    From the Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 80:890-6. 2013
    ..To model the temporal trajectory of β-amyloid accumulation using serial amyloid PET imaging...
  21. pmc Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 135:794-806. 2012
    ..Our analysis suggested that imaging has the potential to be useful to help differentiate C9ORF72 from these other groups at the single-subject level...
  22. pmc A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity
    Christopher G Schwarz
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA
    Neuroimage Clin 11:802-812. 2016
    ....
  23. pmc Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry
    Jonathan Graff-Radford
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Mov Disord 31:989-94. 2016
    ..The clinical course of dementia with Lewy bodies patients is heterogeneous. The ability to more accurately prognosticate survival is important...
  24. doi request reprint Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study
    Ajay Madhavan
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    J Alzheimers Dis 49:633-43. 2016
    ..Different clinical syndromes can arise from Alzheimer's disease (AD) neuropathology, including dementia of the Alzheimer's type (DAT), logopenic primary progressive aphasia (lvPPA), and posterior cortical atrophy (PCA)...
  25. pmc Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Lancet Neurol 15:56-64. 2016
    ..In this longitudinal study, we aimed to estimate rates of transition from a less to a more abnormal biomarker state by age in individuals without dementia, as well as to assess rates of transition to dementia from an abnormal state...
  26. pmc Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings
    Clifford R Jack
    1 Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Brain 138:3747-59. 2015
    ....
  27. doi request reprint Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    J Alzheimers Dis 45:1109-17. 2015
    ..However, little is known about the frequency or distribution of microbleeds in subjects with AD that present with atypical clinical presentations...
  28. pmc The evolution of primary progressive apraxia of speech
    Keith A Josephs
    1 Department of Neurology Behavioural Neurology, Mayo Clinic, Rochester, MN 55905, USA 2 Department of Neurology Movement Disorders, Mayo Clinic, Rochester, MN 55905, USA
    Brain 137:2783-95. 2014
    ..These findings help improve our understanding of primary progressive apraxia of speech and provide some important prognostic guidelines...
  29. pmc Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study
    Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Lancet Neurol 13:997-1005. 2014
    ..We aimed to characterise how typical ageing and preclinical Alzheimer's disease overlap in terms of β-amyloidosis and neurodegeneration...
  30. pmc 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Neurobiol Aging 35:2096-106. 2014
    ..The posterior cingulate and/or precuneus and lateral parietal regions have a unique vulnerability to reductions in glucose metabolic rate as a function both of age and carriage of an APOE ε4 allele...
  31. pmc MRI and MRS predictors of mild cognitive impairment in a population-based sample
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 81:126-33. 2013
    ..To investigate MRI and proton magnetic resonance spectroscopy (MRS) predictors of mild cognitive impairment (MCI) in cognitively normal older adults...
  32. pmc Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
    Clifford R Jack
    Clifford R Jack, Mayo Clinic, Diagnostic Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:1355-65. 2009
    ..This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration...
  33. pmc Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:2932-46. 2009
    ..Our findings suggest behavioural variant of frontotemporal dementia can therefore be subdivided into four different anatomical subtypes...
  34. pmc Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic 200 1st St SW, Rochester, MN 55905, USA
    Neuroimage 39:1186-97. 2008
    ..To develop and validate a tool for Alzheimer's disease (AD) diagnosis in individual subjects using support vector machine (SVM)-based classification of structural MR (sMR) images...
  35. pmc Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly
    Prashanthi Vemuri
    1 Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
    Brain 138:761-71. 2015
    ....
  36. doi request reprint Modeling trajectories of regional volume loss in progressive supranuclear palsy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 28:1117-24. 2013
    ..Decline is mainly linear but can be nonlinear for some regions. The frontal lobe and midbrain seem to be playing the most significant roles in the progressive worsening of clinical signs in progressive supranuclear palsy...
  37. doi request reprint Imaging measures predict progression in progressive supranuclear palsy
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 27:1801-4. 2012
    ..The aim of this work was to determine whether the progressive supranuclear palsy rating scale, a measure of disease severity, is associated with neuroanatomical changes in progressive supranuclear palsy...
  38. pmc Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative
    Clifford R Jack
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 6:212-20. 2010
    ..These experimental sub-studies are designed to demonstrate the feasibility of acquiring useful data in a multicenter (but single vendor) setting for these three emerging MRI applications...
  39. pmc Atrial fibrillation, cognitive impairment, and neuroimaging
    Jonathan Graff-Radford
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA
    Alzheimers Dement 12:391-8. 2016
    ..The objective of our study was to investigate cross-sectional associations of atrial fibrillation with neuroimaging measures of cerebrovascular disease and Alzheimer's disease and their interactions with mild cognitive impairment (MCI)...
  40. pmc Cascading network failure across the Alzheimer's disease spectrum
    David T Jones
    1 Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA 2 Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA
    Brain 139:547-62. 2016
    ..Possible interpretations include that the molecular-level events drive the network failure, a pathological interaction between the network-level and the molecular-level, or other upstream factors are driving both...
  41. pmc Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics
    Christopher G Schwarz
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Neuroimage 94:65-78. 2014
    ..The proposed pipeline produces more plausible results according to each disease's pathophysiology. ..
  42. pmc Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women
    Limor Raz
    Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA
    Neurology 80:911-8. 2013
    ..To determine the association of conventional cardiovascular risk factors, markers of platelet activation, and thrombogenic blood-borne microvesicles with white matter hyperintensity (WMH) load and progression in recently menopausal women...
  43. pmc Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Parkinsonism Relat Disord 18:252-6. 2012
    ..Sample size estimates suggest that treatment trials could be performed over this interval, with rate of midbrain atrophy providing the best outcome measure...
  44. pmc Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease
    Matthew L Senjem
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 26:600-8. 2005
    ....
  45. pmc The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods
    Clifford R Jack
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Magn Reson Imaging 27:685-91. 2008
    ..The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom-based monitoring of all scanners could be used as a model for other multisite trials...
  46. ncbi request reprint Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    Ann Neurol 59:200-3. 2006
    ..To determine the rates of cerebral atrophy and ventricular expansion in six patients with autopsy confirmed progressive supranuclear palsy (PSP) and multiple antemortem volumetric head MRI scans...